INTRODUCTION
Successful human leukocyte antigen (HLA)-matched sibling bone marrow transplants for severe combined immunodeficiency (SCID) were first reported from Minnesota for X-linked SCID in 1968 [1] and for SCID adenosine deaminase deficiency (ADA-SCID) from Boston in 1975 [2] , followed closely by reports of an unrelated donor transplant from New York in 1977 [3] and haploidentical-related donor transplants in New York [4] , California [5] and North Carolina [6] from 1983 to 1986. Similarly, North American centers made important historical contributions in advancing the treatment of non-SCID primary immunodeficiency (PID) with hematopoietic cell transplantation (HCT). Transient reconstitution after matched sibling bone marrow transplant for Wiskott-Aldrich syndrome (WAS) was first reported from Wisconsin in 1968 [7] , followed by successful multilineage reconstitution from Boston in 1978 [8] . Investigators from New York described the use of busulfan and cyclophosphamide in three patients with WAS in 1981 [9] , establishing the backbone for myeloablative transplant for other nonmalignant disorders, including other PIDs, hemoglobinopathies and inborn errors of metabolism.
In contrast to Europe where an active multiinstitutional registry has reported outcomes after transplant since 1968 [10] , results from North America after 1985 have been mostly limited to single institution studies. The largest of these describes results of up to 161 unconditioned matched sibling and T cell-depleted haploidentical transplants for SCID from Duke University Medical Center, with 77% survival and high rates of T cell reconstitution, albeit sometimes after multiple infusions [11] [12] [13] . The only combined institution study [14] reported outcome of 94 infants transplanted in Toronto, Canada and Brescia, Italy; survival in the 41 matched unrelated donor recipients was 80% and in the T cell-depleted haploidentical recipients only 50%, perhaps related to the receipt of conditioning.
The participants at two workshops held at National Institutes of Health (NIH) in 2007 and 2008 [15, 16] concluded that such single institution or limited multiinstitution studies of rare PIDs were insufficient, as no single center's experience was large enough to appreciate the complexities of these disorders and the variety of therapeutic approaches available. That each center tended to utilize their own preferred protocols made the study of this patient population very difficult. In light of this, in 2009, the Primary Immune Deficiency Treatment Consortium (PIDTC) was formed. The PIDTC is an NIH-funded group of 43 centers whose goals are to analyze the results of HCT, gene therapy and enzyme replacement therapy for PIDs in North America, collaborate with Patient Advocacy Groups, promote involvement of trainees and junior faculty in the study and definitive cure of PID and foster international collaboration to study PID [17 & ]. The ultimate goal of the consortium is to develop prospective intervention trials. The following review focuses on PIDTC studies of SCID and key advances in the field of HCT for non-SCID PIDs.
NEWBORN SCREENING FOR SCID AND ITS IMPACT ON SCID DIAGNOSIS AND TREATMENT
Previous studies [10, 11, 18] have noted better survival after HCT for SCID in young infants, either under 3.5 months or under 6 months of age at the time of transplant, a finding confirmed in the United Kingdom and by the European SCETIDE registry [19, 20] . These data combined with the known negative impact of infection on survival [10, 20] The introduction of NBS for SCID in the United States emphasized the need for well conducted prospective natural history and retrospective studies of outcomes after HCT, laying the groundwork for developing prospective multicenter therapeutic trials that focused on the special needs of very young infants. To facilitate determination of eligibility for such studies, the PIDTC established diagnostic criteria for typical SCID and SCID-related disorders, including leaky SCID, Omenn's syndrome and reticular dysgenesis, and further refined these in the course of reviewing newly identified and historical cases of SCID undergoing HCT at PIDTC centers [25 & ]. Among 50 newly diagnosed infants with SCID identified at 17 centers from August 2010 to May 2012, 13 of 50 (26%) had SCID-related disorders, a higher frequency than previously anticipated [26 & ].
KEY POINTS
Age and infectious status are the key determinants of survival in SCID patients undergoing HCT, with patients under 3.5 months and patients of any age who do not have active infection having the best outcome.
The implementation of newborn screening for SCID in the United States is anticipated to lead to virtually universal survival in these patients.
Chemotherapy conditioning, if given, is associated with better immune reconstitution in patients with SCID, but has high impact on patients with SCID caused by Artemis deficiency; long-term effects on other genotypes must be explored.
Advances in the safety and efficacy of HCT for WAS and CGD have expanded the range of patients for whom this treatment may be offered.
Of the 37 infants with typical SCID, the 12 identified by universal NBS and the 10 by family history had a younger age at diagnosis (14 vs. 179 days) and at HCT (67 vs. 214 days) than the 15 identified by symptoms. Currently, 21 states are screening for SCID, accounting for 62% of births in the United States. As more states establish SCID NBS programs, further information on the phenotypic and genotypic distribution of screened vs. nonscreened SCID populations and importantly, on the anticipated improvement in outcomes for SCID will be forthcoming.
UPDATE ON OUTCOMES AFTER HCT FOR SCID IN NORTH AMERICA
Transplant centers in North America have followed disparate approaches to alternative donor transplant for SCID patients who lack a matched sibling donor, namely T cell-depleted transplant from a haplocompatible-related donor with or without pretransplant conditioning vs. a well matched unrelated donor or cord blood transplant, most often with busulfan-based, myeloablative or reduced intensity conditioning. Although all of these approaches result in T cell reconstitution, many have noted that B cell reconstitution is more variable and is related to conditioning [27] , that is, conditioning with busulfan or similar stem cell cytotoxic agents is associated with a higher chance of engraftment with donor-derived B cells and also a higher chance of being independent of intravenous immunoglobulin substitution (IVIG). The PIDTC conducted an analysis of 5-year survival and immune reconstitution of 240 patients with typical SCID, defined by PIDTC criteria after rigorous central review, transplanted at 25 North American centers from 2000 to 2009 [28 && ]. In addition to confirming key findings of registry studies in Europe, namely improved survival in young infants (<3.5 months at time of HCT) and poorer survival in those with active infection, this study dissected the relative importance of age and infection, demonstrating that older infants whose infection had resolved had similar survival to older infants who were never infected or young infants with or without infection (82 vs. 90 vs. 94%, respectively). Within these categories, survival after haploidentical transplant without conditioning, haploidentical transplant with conditioning, matched unrelated donor transplant and umbilical cord transplant were all similar, further supporting the importance of early identification and protection from infection on outcome. Among actively infected infants, survival after unrelated donor, umbilical cord blood or haploidentical transplant with conditioning were inferior (53, 40, 39%, respectively) to haploidentical transplant without conditioning (65%), and all were far inferior to matched sibling donor transplants (93%). Among survivors, although 92% of patients had recovery of T cell function, only 70% had a CD3 þ T cell count above 1000/ml, 49% had a CD4 þ T cell count above 500/ml and 74% were independent from IVIG therapy at 2-5 years posttransplant. The association with IVIG independence and busulfan-based conditioning was confirmed; interestingly, conditioning was associated with higher CD3 þ T and higher naïve CD45RA þ CD4 þ T cell counts. This study only analyzed 5-year survival; ongoing PIDTC retrospective and cross-sectional studies will describe the adverse late effects of conditioning on babies with SCID.
KEY COLLABORATIVE STUDIES IN SUBPOPULATIONS OF SCID
Retrospective registry studies of SCID, although informative, do not have the granularity of data required to answer questions for specific SCID genotypes or outcomes after specific transplant approaches. Two collaborative international studies, including patients from both North American and Europe have yielded important insights for specific populations.
T -B -NK þ SCID represents about 15% of all SCID patients on the basis of recent NBS data (J.S. Puck, personal communication). The most common cause of T -B -NK þ SCID is biallelic mutations in one of the recombination-activating genes (RAG1, RAG2) followed by defects in DCLRE1C, resulting in Artemis deficiency (ART-SCID). There is a high incidence of ART-SCID among Athabascan-speaking Native Americans, in particular the Navajo and Apache Indians [29] . These abnormalities result in absent or defective V(D)J recombination and the absence of both T and B lymphocyte development [30] . Interestingly, although RAG1/2 initiates the process of V(D)J recombination, the role of Artemis is to repair and recombine the various DNA segments that ultimately code for T and B cell receptors that result in the diversity of the adaptive immune system. Artemis is a critical component of the nonhomologous end joining (NHEJ) pathway of DNA repair and mutations in DCLRE1C or other key NHEJ genes, including PRDKC (DNA-PKcs), LIG4 (DNA ligase) and NHEJ1 (Cernunnos or XLF), all typically result not only in T -B -NK þ SCID but also increased sensitivity to alkylating agents and ionizing radiation [31, 32] .
Previous studies suggested that ART-SCID patients have a poorer outcome when exposed to alkylating agents as part of their pretransplant conditioning [33] . Recently, investigators in San Francisco, Paris and Ulm collaborated to compare early and late outcomes of 69 patients with ART-SCID to 76 patients with RAG1/2-SCID [34 && ]. There were no differences in survival regardless of exposure to alkylating agents. Secondary malignancies were not found, and immune reconstitution was comparable. However, in patients surviving beyond 2 years posttransplant, the ART-SCID patients had a significantly higher occurrence of infections (34 vs. 13%), and were more likely than RAG-SCID patients to have short stature after receiving alkylating agents (49 vs. 9%). Also, abnormal dental development (21 vs. 0%) and nonautoimmune-mediated endocrine late effects (15 vs. 0%) were associated with alkylating therapy in ART-SCID patients compared with those with RAG-SCID. Thus, identifying those patients with a defect in the NHEJ pathway prior to instituting transplant therapy and characterizing the late effects of high-dose chemotherapy conditioning in very young babies are critical.
Matched Transplant Inborn Errors Working Party study, analyzing 37 unrelated donor and 66 matched sibling donor transplants occurring at 16 centers between July 1993 and November 2012. T cell reconstitution was comparable between the recipients of unrelated donor and matched sibling donor grafts (92 vs. 97%, respectively). However, in contrast to 72% of the matched sibling donor recipients, only 17% (P < 0.001) of the unrelated donor recipients achieved B cell reconstitution. Although survival was worse for the unrelated donor compared with the matched sibling donor recipients (71 vs. 92%, P < 0.01), if serotherapy (antithymocyte globulin or alemtuzumab) was used prior to unrelated donor transplant, 5-year overall survival for unrelated recipients was 100%. Acute and chronic graftversus-host disease (GVHD) was also higher in the unrelated donor group, although this might be in part because of the relatively limited GVHD prophylaxis that was used. Thus, the use of unrelated donor grafts without preconditioning may be considered for patients with SCID, provided appropriate GVHD prophylaxis including serotherapy is administered prior to the transplant. Further studies are needed to define optimal GVHD regimens. . Lineage-specific chimerism was unstable in the first year posttransplant in 20% of patients, and mixed chimerism was more frequent among recipients of unrelated donor transplants. Myeloid chimerism of more than 50% was generally associated with platelet counts above 50 000/ml. Similarly to a previous study from Europe [40] , the authors also found an association between clinical autoimmunity and having lower donor chimerism in T, B and myeloid lineages [37] . Improvements in HLA typing, expansion of the donor registries and targeted delivery of IV busulfan have led to substantial improvements in outcomes for CGD after unrelated donor transplant, even in patients with severe infections or inflammatory disease [41] . The European experience reported from 1985 to 2000 of 27 patients showed that all four patients with active fungal infections at time of transplant died [42] . In contrast, two single institution reports of 11 children at Baylor Texas Children's Hospital and 12 children at Duke University have demonstrated excellent survival and engraftment [43, 44] . One reported 100% survival of four matched sibling and seven unrelated donor grafts, with no graft failures, despite a high percentage of high-risk patients and myeloablative conditioning [43] . The other reported 100% survival of five matched sibling bone marrow, six unrelated umbilical cord blood and one sibling umbilical cord blood recipients despite two graft failures and myeloablative conditioning [44] . Although all but two patients in these series had more than 90% donor chimerism, the rate of acute and chronic GVHD after umbilical cord blood transplant remained substantial.
KEY SINGLE INSTITUTION AND COLLABORATIVE STUDIES IN WAS AND CGD

CONCLUSION
The formation of a multiinstitutional consortium dedicated to studying and improving cellular therapy for PID in North America is now bearing fruit with regard to prospective natural history studies and retrospective studies of outcomes, particularly for SCID. The implementation of NBS for SCID in the United States presents unique opportunities to examine the impact of early diagnosis and treatment on survival and immune reconstitution, study the psychosocial impact of the diagnosis of SCID in asymptomatic newborns, and devise well tolerated and effective methods that minimize toxicity in very young infants. Plans are underway for a dose escalation PIDTC study of busulfan in infants identified at birth, to determine the minimum exposure that results in T cell and B cell reconstitution.
Prospective natural history, retrospective and cross-sectional studies similar to those conducted in SCID are planned for WAS and CGD by the PIDTC, with anticipated enrollments of 355 and 273 patients, respectively. The CGD study [45] will compare a cohort of 475 untransplanted contemporary patients, matching for NADPH oxidase activity, which has been shown to correlate with survival. The CGD study includes international collaborators and studies of quality of life in WAS patients with and without HCT. Nearly 50 years after the first successful transplant for PID, investigators in the field are now poised to make advances in the biology and treatment of PID that can only be afforded by multiinstitutional cross-national cooperation. Program (Translational Investigator Service Award to S.-Y.P.). The PIDTC is a part of the NIH Rare Diseases Clinical Research Network (RDCRN). The views expressed in written materials or publications do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
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The study defined what has been suggested from smaller series, namely that defects in DNA repair in SCID due to Artemis deficiency result in important late toxicities after exposure to alkylating agents administered as conditioning. This study can guide clinicians in selecting the HCT regimen for RAG1/2 vs. ART-SCID and provide anticipatory counseling for families regarding expected outcome. Because of improvements in HLA-matching techniques, it has been suspected that grafts from fully matched unrelated donor at high resolution, whether derived from volunteer adults or umbilical cord blood, might reconstitute immunity in SCID patients even when administered without conditioning, as is typically done for matched sibling-related grafts. This multiinstitutional international study gathered such cases of SCID and retrospectively compared survival and immune reconstitution. Although outcomes of the unrelated donor transplants were inferior to matched sibling transplants, the demonstration that the approach is feasible and results in high rates of T cell engraftment provides an option to clinicians facing the dilemma of how to treat a child with SCID who lacks a matched sibling donor and who cannot tolerate chemotherapy conditioning.
